Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Oct 15, 2024

TEL AVIV, Israel ─ October 15, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

Oct 1, 2024

TEL AVIV, Israel ─ October 1, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

Aug 28, 2024

TEL AVIV, Israel ─ August 28, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

Aug 21, 2024

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)──

All News

Stock Info
NASDAQCMMB
Events
Friday, October 18, 2024
4:25pm - 5:30pm MDT

Session: Industry Updates: Ongoing Clinical Trials in PSC
Speaker: Matt Frankel, MD, Chemomab Chief Medical Officer
Format:  In-person presentation to Conference participants
Information: https://web.cvent.com/event/285a8cb1-8583-4467-ac01-1bb790d0f3fd/websitePage:f6463205-0db9-4bdc-90c5-b5303d6a3fbe

All Events

Featured Presentations

Download

Chemomab Corporate Overview - September 2024